Business Wire

MUSE

20.10.2021 15:02:13 CEST | Business Wire | Press release

Share
Interaxon Inc. (Muse®) Launches the Latest in Non-Pharmaceutical Sleep Support: EEG-Powered ‘Digital Sleeping Pills’ That Provide Immediate & Intelligent Support for Falling Asleep & Nighttime Interruptions

Interaxon Inc. (Muse® ), a leading consumer neurotechnology and meditation company, today announced the launch of the second generation of its popular EEG meditation & sleep headband, Muse S. This updated plush brain-sensing headband uses real-time biofeedback to help you learn the art of mediation as well as help you fall asleep, stay asleep and now go back to sleep if you awaken during the night.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211020005215/en/

Alongside the launch of the updated Muse S headband, Interaxon is launching an intelligent new kind of EEG-powered sleep experience that is designed to help put you to sleep and guide you back to sleep if you’ve woken during the night.

Interaxon has been excited to offer this never-before-seen sleep intervention after building on their successful release of sleep content & EEG sleep tracking insights to support healthy sleep habits. A recent 2021 study led by Western University, Cambridge Brain Science, Hatch, and Interaxon that used Muse S EEG-sleep support technology showed a 20% improvement in the Pittsburgh Sleep Quality Index, relative to controls wanting to improve their sleep.

“For many of us, increasingly busy days translate into busy minds at night and restless sleep. While sleep tracking can be helpful to gain insights on trends and changes in your sleep quality, tracking your sleep doesn’t provide immediate relief when you need it most,” said Walter Greenleaf, Chief Science Officer at Interaxon (Muse®). “According to the CDC, more than a third of American adults are not getting enough sleep on a regular basis with less than seven hours per day.1 This innovative new solution can help users get the rest they need to improve their overall wellness with a non-pharmaceutical sleep aid.”

Digital Sleeping Pills (DSPs)

Muse Digital Sleeping Pills or DSPs are designed to help you through the wind-down process by responding to your brain’s rhythms and helping you disengage from your busy mind. Muse S detects the natural changes in your brain activity as you fall asleep and uses those changes to gently fade out your audio to cue your brain that it’s time for sleep. If you wake in the night, Muse S uses the same Smart-Fade technology to automatically fade in the DSP content to guide you back to sleep again.

Sleep content preferences can vary widely from person to person. Some people are looking for a more engaging story to keep their mind from getting stuck in ruminating thoughts, while others may find a story too exciting to fall asleep to and prefer a softer, guided meditation or ambient soundscape. Depending on what type of content helps you fall asleep best, you can select a variety of different DSP’s to help you on your journey including all-new:

  • Original, Classic, and Adventure Sleep Stories that have a voice narration of some of your favorite childhood stories & a variety of new original stories
  • Ambient Sleep Soundscapes that offer soothing ambient music and harmonized sounds without a voice narrative
  • Biofeedback Sleep Soundscapes that offer nature sounds and music that respond to biofeedback without a voice narrative
  • Guided Sleep Meditations that have a meditation teacher guide you through a relaxing sleep meditation

In addition to the advanced EEG technology that Muse® is known for, the all-new second-generation Muse® S has improved signal quality for increased accuracy and enhanced battery performance with up to 50% reduction in charging time. Additionally, improved fit for a wider range of head sizes has been achieved with the same comfortable, adjustable, and washable fabric band.

Pricing and Availability

Muse® S (Gen 2) is now available for $399.99 USD at www.choosemuse.com and will be available on Amazon North America starting in 2022. Both first and second-generation Muse® S headbands will have access to the new Digital Sleep Pill (DSP) features free of charge with Gen 1 users gaining access in December of 2021.

To unlock Biofeedback+ and unlimited access to 500+ meditations with new content released monthly, you can subscribe to the Muse Premium Subscription for $12.99 USD per month or $94.99 USD per year.

In addition to a rich content library of more than 500 meditations from renowned meditation teachers, unlock access to a variety of relaxation techniques, Go-to-Sleep soundscapes, and in-depth courses with step-by-step instructions, such as The Sleep Basics course by Dr. Shelby Harris, an expert in behavioral sleep medicine. Additionally, you’ll have access to Biofeedback+ which is designed to allow you to see how your brain and body responds to external content whether it be music in Spotify, Audiobooks, or meditations in Headspace.

Now available at www.choosemuse.com .

About Muse ® by Interaxon Inc. :

At Muse®, our team of neuroscientists, meditation teachers, and engineers based out of Toronto who develop state-of-the-art experiences using research-grade EEG technology. Our goal is to help individuals build a rewarding meditation practice and live healthier, happier, more connected lives through human-centered technology. Our award-winning neurofeedback devices, and premium content offering of guided meditations with responsive learning functionality, is designed to help users meditate by providing real-time audio feedback on their meditative state through the Muse® companion app. We make the intangible, tangible. Muse is headquartered in Toronto, Canada, and has subsidiaries in the U.S. and Ireland.

More information about Muse® is available at www.choosemuse.com .

Milestones we’re excited about:

  • More than 500,000 Musers globally
  • Accessible: Muse is available in four languages, including English, Spanish, French and German
  • Sessions of meditation with Muse ®: Over 100 million minutes to date and currently one of the largest brain data (EEG) collections in the world.
  • Research institutions using Muse®: The Mayo Clinic, NASA, Harvard, MIT, U of T, UCL, UCSD, Inria, UVic, UBC, and many more.
  • Meditating with Muse® works: Muse has been used in over 200 published studies, including Mayo Clinic who demonstrated meditating with Muse increases quality of life, and decreases stress and fatigue in cancer patients.
  • Untangle Podcast : With more than 7 million plays, Untangle hosts Patricia Karpas and Ariel Garten interview thought-provoking authors, experts and leaders in areas related to mindfulness, sleep, neuroscience, brain health practices, and more.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Estithmar Holding Pays the Third Semi-Annual coupon of the 8.75% Sukuk Tranche12.3.2026 21:50:00 CET | Press release

Estithmar Holding Q.P.S.C. has paid the third semi-annual coupon of its Qatari Riyal-denominated Sukuk (first tranche), at an annual profit rate of 8.75%. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260312880092/en/ Estithmar Holding Pays the Third Semi-Annual coupon of the 8.75% Sukuk Tranche (Photo: AETOSWire) The first tranche, part of the company’s broader Sukuk program valued at QAR 3.4 billion and listed on the London Stock Exchange’s International Securities Market, was issued in August 2024. The issuance attracted a diverse pool of institutional investors including banks, insurance companies, and asset managers, with strong interest from both government-affiliated and private institutions. This demand reflects growing investor confidence in Estithmar Holding’s ability to deliver sustained value to stakeholders. EstithmarHolding was recently included in the FTSE Russell Global Equity Index, in Qatar’s Mid-Cap segme

Andersen Consulting styrker sine kompetencer i samarbejde med Acumen Learning12.3.2026 21:36:00 CET | Pressemeddelelse

Andersen Consulting udvider sin platform gennem en samarbejdsaftale med Acumen Learning, en amerikansk virksomhed, der specialiserer sig i træning i forretnings- og økonomiforståelse med henblik på lederudvikling og salgsresultater. Acumen Learning blev stiftet i 2002 og samarbejder med Fortune 500-virksomheder for en bedre finansiel forståelse, strategisk tænkning og beslutningstagning på alle niveauer. Med udgangspunkt i principperne fra deres bestsellerbøger "Seeing the Big Picture" og "Business Acumen for Sales Success" klæder deres programmer ledere og teams på til at afstemme beslutninger med virksomhedsstrategier, fremme resultater og styrke kunderelationer. Acumen Learning er målrettet brancher som sundhedssektoren, energi og teknologi og giver fagfolk mulighed for at omsætte forretningsviden til håndgribelige resultater. "Hos Acumen Learning er vores mission at styrke det enkelte menneske ved at skabe forretningskyndige fagfolk, der gør en forskel i deres karrierer," udtalte K

REPLY: The Board of Directors Approved the Draft Financial Statements for the Year 202512.3.2026 15:38:00 CET | Press release

All economic indicators are positive.Consolidated turnover of €2,483.6 million (€2,300.5 million in 2024);EBITDA at €467.6 million (€410.6 million in 2024);EBIT at €391.7 million (€330.4 million in 2024)Group net profit at €250.9 million (€211.1 million in 2024)Approval of the proposed dividend distribution of €1.35 per share. Today the Board of Directors of Reply S.p.A. [MTA, STAR: REY] approved the draft financial statement for the year 2025, which will be submitted for approval to the Shareholders’ Meeting to be held in first call in Turin on 23 April 2026. The Reply Group closed 2025 with a consolidated turnover of €2,483.6 million, an increase of 8.0% compared to €2,300.5 million in 2024. All indicators are positive for the period. Consolidated EBITDA was €467.6 million, an increase of 13.9% compared to €410.6 million at December 2024. EBIT, from January to December, was at €391.7 million, which is an increase of 18.5% compared to €330.4 million at December 2024. The Group net pro

LZE GmbH Introduces Fraunhofer’s RFicient® Technology to the Market12.3.2026 14:51:00 CET | Press release

LZE GmbH is expanding its technology transfer portfolio and making the RFicient® ultra-low-power wake-up receiver technology from the Fraunhofer Institute for Integrated Circuits IIS available for the first time as a standard chip for close-to-production industrial applications. The solution enables energy-efficient IoT designs that remain continuously reachable while consuming only microamps – a key step for long-lasting, low-maintenance IoT products. LZE GmbH drives technology transfer to market: standard chip availability for close-to-production applications As a bridge between research and industry, LZE GmbH is making it easier for companies to access innovative technologies and helping them to quickly and reliably transform new developments into market-ready solutions. With RFicient®-IC (FH101RF), LZE is providing another high-tech product that comes directly from Fraunhofer research and can now be ordered in volume and integrated into close-to-production product development for t

Owkin Creates New Spin out Waiv, Formerly Owkin Dx, With $33M Financing12.3.2026 14:30:00 CET | Press release

Investment lead by OTB Ventures and Alpha Intelligence CapitalWaiv develops AI-powered precision testing to better identify and stratify patients in the clinic and in clinical trials, transforming patient careWaiv extends Owkin’s strategy of real-world validation for its AI Owkin, the AI company on a mission to solve the complexity of biology, today announced the spin out of Waiv, formerly known as Owkin Dx. The move follows significant investor interest and positions Waiv to bring AI-powered precision testing for better identification of patients in the clinic and in clinical trials, to transform patient care. This follows on from the successful launch of Bioptimus, an Owkin incubated company, in February 2024. Waiv translates AI innovation into real-world clinical impact, developing tests that predict biomarkers and patient outcomes, including RlapsRisk BC for prognostic risk profiling. With multiple tests already in use in clinical settings, its deployment platform Destra, and colla

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye